Human FGFR1 alpha (IIIc) Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB11336

R&D Systems, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

Flow Cytometry

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2B Clone # 1058809

View all FGFR1 alpha Antibodies »

Product Specifications

Immunogen

Human embryonic kidney cell, HEK293-derived human FGFR1 alpha
Arg22-Glu376
Accession # P11362.3

Specificity

Detects human FGFR1 alpha (IIIc) in direct ELISA.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2B

Scientific Data Images for Human FGFR1 alpha (IIIc) Antibody

Detection of FGFR1 alpha in HEK293 cells transfected with hFGFR1 and eGFP cells by Flow Cytometry.

HEK293 cells transfected with hFGFR1 and eGFP were stained with either (A) Mouse Anti-Human FGFR1 alpha (IIIc) Monoclonal Antibody (Catalog # MAB11336) or (B) Mouse IgG2B Isotype Control (Catalog # MAB004). View our protocol for Staining Membrane-associated Proteins.

Applications for Human FGFR1 alpha (IIIc) Antibody

Application
Recommended Usage

Flow Cytometry

0.25 µg/106 cells
Sample: HEK293 cells transfected with hFGFR1 and eGFP

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: FGFR1 alpha

Fibroblast growth factor receptor 1 (FGFR1) belongs to a family of type I transmembrane tyrosine kinases which mediate the biological functions of FGFs that are involved in a multitude of physiological and pathological cellular processes (1). The FGFR family is comprised of 4 structurally conserved members (FGFR1-4) all possessing an extracellular domain (ECD) with three immunoglobulin (Ig)-like domains, an acid-box region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and cytoplasmic split tyrosine-kinase domain (1, 2). The ECD of mature, full-length FGFR1 shares 98% amino acid sequence identity with mouse FGFR1. Alternative splicing generates multiple forms of FGFR1-3, each with unique signaling characteristics (1-3). For FGFR1, alternative splicing of the ECD generates FGFR1A, FGFR1B, and FGFR1G isoforms of the receptor with the A isoform containing three Ig domains, while the B and G isoforms lack the N‑terminal IgI domain (3). Additional splicing of the IgIII domain, results in IIIa, IIIb, or IIIc isoforms (3). Only the alpha isoform has been identified for FGFR3 and FGFR4 and FGFR4 also lacks the IIIb and IIIc splicing events (4). The FGFR splice variants also exhibit distinct and varying binding affinities for different FGF ligands (2). FGFRs mediate the FGF signaling cascade which regulate developmental processes including cellular proliferation, differentiation, and migration, morphogenesis, and patterning (5). FGFRs transduce the signals through three dominant pathways including RAS/MAPK, PI3k/AKT, and PLC gamma (6). FGFR1 the most abundant FGFR and is widely expressed in many adult human tissues, but the splice variants display distinct tissue-specific differences with IIIc splice variants expressed in mesenchymal tissue (4, 7, 8). Mutations in FGFR1 or misregulation of FGFR1 mediated signaling is found in multiple diseases, with FGFR1A(IIIc) specifically upregulated, from breast and pancreatic cancer to Pfeiffer syndrome and osteoarthritis (4, 9-11). A soluble version of the FGFR1A(IIIc) splice variant has shown anti-angiogenic and anti-proliferative properties in multiple cancer cell line models (11).

References

  1. Ornitz, D.M. and Itoh, N. (2015) Wiley Interdiscip. Rev. Dev. Biol. 4:215.
  2. Zhang, X. et al. (2006) J Biol. Chem. 281:15694.
  3. Ferguson, H.R. et al. (2021) Signaling Cells 10:1201.
  4. Holzmann, K. et al. (2012) J Nucleic. Acids 2012:950508.
  5. Xie, Y. et al. (2020) Sig. Transduct. Target Ther. 5:181.
  6. Mossahebi-Mohammadi, M. et al. (2020) Front Cell Dev. Biol. 18:79.
  7. Hughes, S.E. (1997) J. Histochem. Cytochem. 45:1005.
  8. Delezoide, A.L. et al. (1998) Mech. Dev. 77:19.
  9. Yamashita-Sugahara, Y. et al. (2016) Sci. Rep. 6:35908.
  10. Teven, C.M. et al. (2014) Genes Dis. 1:199.
  11. Babina, I. and Turner, N. (2017) Nat. Rev Cancer 17:318.

Long Name

Fibroblast Growth Factor Receptor 1 alpha

Alternate Names

FGF R1a

UniProt

P11362.3

Additional FGFR1 alpha Products

Product Documents for Human FGFR1 alpha (IIIc) Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human FGFR1 alpha (IIIc) Antibody

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.